Identification

Name
Dexibuprofen
Accession Number
DB09213
Type
Small Molecule
Groups
Approved, Investigational
Description

Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen [A19257] and displays improved oral bioavilability [4]. *For Metabolism, Enzymes, Carriers, Transporters Sections, refer to Ibuprofen (DB01050)

Structure
Thumb
Synonyms
  • (+)-(S)-p-isobutylhydratropic acid
  • (2S)-2-(4-isobutylphenyl)propanoic acid
  • (S)-α-methyl-4-(2-methylpropyl)benzeneacetic acid
  • d-ibuproten
Categories
UNII
671DKG7P5S
CAS number
51146-56-6
Weight
Average: 206.2808
Monoisotopic: 206.13067982
Chemical Formula
C13H18O2
InChI Key
HEFNNWSXXWATRW-JTQLQIEISA-N
InChI
InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
IUPAC Name
(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
SMILES
[H][C@@](C)(C(O)=O)C1=CC=C(CC(C)C)C=C1

Pharmacology

Indication

Similar indications as ibuprofen; to be used as a symptomatic treatment for pain and inflammation in rheumatic disease such as osteoarthritis and rheumatoid arthritis, as well as other musculoskeletal disorders. It is also used to reduce oral postoperative pain and alleviate fever.

Pharmacodynamics

A non-steroidal anti-inflammatory drug (NSAID) with non-narcotic analgesic and antipyretic properties. Like ibuprofen and other common NSAIDs, dexibuprofen works by inhibiting the arachidonic acid oxidation by the fatty acid cyclooxygenase (COX) enzyme. It is more selective towards COX-2 (generally irreversible time-dependent inhibition) but also is weakly COX-1 selective (generally rapid inhibition).

Mechanism of action

Like common NSAIDs, dexibuprofen is an active enantiomer of ibuprofen that suppresses the prostanoid synthesis in the inflammatory cells via inhibition of the COX-2 isoform of the arachidonic acid COX. Attenuating the synthesis of prostaglandins and thromboxanes gives the drug three major therapeutic actions. Anti-inflammatory action comes from decreased prostaglandin E2 and prostacyclin leading to decreased vasodilation and oedema that enhances vascular permeability and activity of inflammatory mediators. Decreased prostaglandin levels in the hypothalamus confers the antipyretic effect of the drug. Analgesic effect stems from decreased prostaglandin levels that sensitize the nociceptors to inflammatory mediators at sites of pain and enhance transmission from afferent pain fibers at the spinal cord [7].

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
UApoptosis regulator Bcl-2
negative modulator
Human
UThrombomodulin
modulator
Human
UTissue-type plasminogen activator
modulator
Human
UFatty acid-binding protein, intestinal
binder
Human
UPeroxisome proliferator-activated receptor gamma
activator
Human
UCystic fibrosis transmembrane conductance regulator
inhibitor
Human
Absorption

The time it take to reach peak plasma concentration is 2.25-5 hours post-administration of oral tablets containing 300mg of dexibuprofen [3].

Volume of distribution
Not Available
Protein binding

Extensive binding to plasma albumin, as expected for ibuprofen.

Metabolism

Refer to ibuprofen (DB01050)

Route of elimination

Mainly renal excretion

Half life

Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [3].

Clearance
Not Available
Toxicity

Unwanted effects include dyspepsia, nausea, vomiting, and other gastrointestinal effects such as risk of hemorrhage. Skin reactions, reversible renal insufficiency, and adverse cardiovascular effects such as hypertension may occur. A study reports that like ibuprofen, dexibuprofen inhibited platelet function with similar intensity but exerted a reversible effect for 24 h after the last dose [6]. Oral LD50 value in rats is 636 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Dexibuprofen.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Dexibuprofen.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Dexibuprofen.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Dexibuprofen.Experimental, Illicit
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Dexibuprofen.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Dexibuprofen.Approved, Experimental, Investigational
AcenocoumarolDexibuprofen may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Dexibuprofen.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Dexibuprofen.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Dexibuprofen.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Dexibuprofen.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Dexibuprofen.Experimental, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Dexibuprofen.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Dexibuprofen.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Dexibuprofen.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Dexibuprofen.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Dexibuprofen.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Dexibuprofen.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Dexibuprofen.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Dexibuprofen.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Dexibuprofen.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Dexibuprofen.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Dexibuprofen.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Dexibuprofen.Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Dexibuprofen.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dexibuprofen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dexibuprofen.Approved, Investigational
BazedoxifeneDexibuprofen may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Dexibuprofen.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Dexibuprofen.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Dexibuprofen.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Dexibuprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Dexibuprofen.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Dexibuprofen.Approved, Vet Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Dexibuprofen.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Dexibuprofen.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Dexibuprofen.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Dexibuprofen.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Dexibuprofen.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Dexibuprofen.Experimental
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dexibuprofen.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Dexibuprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Dexibuprofen.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Dexibuprofen.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Dexibuprofen.Approved, Investigational, Vet Approved
ChlorotrianiseneDexibuprofen may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Dexibuprofen.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Dexibuprofen.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Dexibuprofen.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Dexibuprofen.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Dexibuprofen.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Dexibuprofen.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Dexibuprofen.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Dexibuprofen.Approved
ClorindioneDexibuprofen may increase the anticoagulant activities of Clorindione.Experimental
Conjugated estrogensDexibuprofen may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Dexibuprofen.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Dexibuprofen.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Dexibuprofen.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Dexibuprofen.Approved, Investigational
DaidzeinDexibuprofen may increase the thrombogenic activities of Daidzein.Experimental
DapoxetineDapoxetine may increase the antiplatelet activities of Dexibuprofen.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Dexibuprofen.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Dexibuprofen.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Dexibuprofen.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Dexibuprofen.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Dexibuprofen.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Dexibuprofen.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Dexibuprofen.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Dexibuprofen.Approved, Vet Approved
DicoumarolDexibuprofen may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolDexibuprofen may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolDexibuprofen may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Dexibuprofen.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Dexibuprofen.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexibuprofen.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Dexibuprofen.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Dexibuprofen.Approved
DiphenadioneDexibuprofen may increase the anticoagulant activities of Diphenadione.Experimental
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Dexibuprofen.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Dexibuprofen.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Dexibuprofen.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Dexibuprofen.Investigational
EpimestrolDexibuprofen may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Dexibuprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Dexibuprofen.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Dexibuprofen.Approved
EquolDexibuprofen may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
EstradiolDexibuprofen may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateDexibuprofen may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateDexibuprofen may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateDexibuprofen may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolDexibuprofen may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedDexibuprofen may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneDexibuprofen may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Dexibuprofen.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Dexibuprofen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Dexibuprofen.Experimental
Ethinyl EstradiolDexibuprofen may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateDexibuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Dexibuprofen.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Dexibuprofen.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Dexibuprofen.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Dexibuprofen.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Dexibuprofen.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Dexibuprofen.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Dexibuprofen.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Dexibuprofen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Dexibuprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Dexibuprofen.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Dexibuprofen.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Dexibuprofen.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Dexibuprofen.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Dexibuprofen.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dexibuprofen.Approved, Investigational
FluindioneDexibuprofen may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Dexibuprofen.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Dexibuprofen.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Dexibuprofen.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Dexibuprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Dexibuprofen.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Dexibuprofen.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Dexibuprofen.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Dexibuprofen.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Dexibuprofen.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Dexibuprofen.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Dexibuprofen.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Dexibuprofen.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Dexibuprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Dexibuprofen.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Dexibuprofen.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dexibuprofen.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Dexibuprofen.Approved, Investigational, Withdrawn
GenisteinDexibuprofen may increase the thrombogenic activities of Genistein.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Dexibuprofen.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Dexibuprofen.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Dexibuprofen.Investigational
HexestrolDexibuprofen may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Dexibuprofen.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dexibuprofen.Approved, Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Dexibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Dexibuprofen.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Dexibuprofen.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Dexibuprofen.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Dexibuprofen.Investigational, Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Dexibuprofen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Dexibuprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Dexibuprofen.Withdrawn
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Dexibuprofen.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Dexibuprofen.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Dexibuprofen.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexibuprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Dexibuprofen.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Dexibuprofen.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Dexibuprofen.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Dexibuprofen.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Dexibuprofen.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Dexibuprofen.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Dexibuprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Dexibuprofen.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dexibuprofen.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Dexibuprofen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Dexibuprofen.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexibuprofen.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Dexibuprofen.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Dexibuprofen.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Dexibuprofen.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Dexibuprofen.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexibuprofen.Approved
MestranolDexibuprofen may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Dexibuprofen.Approved, Investigational, Withdrawn
MethallenestrilDexibuprofen may increase the thrombogenic activities of Methallenestril.Experimental
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dexibuprofen.Approved, Vet Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dexibuprofen.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Dexibuprofen.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Dexibuprofen.Approved, Vet Approved
MoxestrolDexibuprofen may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dexibuprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexibuprofen.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Dexibuprofen.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Dexibuprofen.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Dexibuprofen.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Dexibuprofen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Dexibuprofen.Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Dexibuprofen.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Dexibuprofen.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Dexibuprofen.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Dexibuprofen.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dexibuprofen.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dexibuprofen.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Dexibuprofen.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dexibuprofen.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dexibuprofen.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Dexibuprofen.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Dexibuprofen.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Dexibuprofen.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Dexibuprofen.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Dexibuprofen.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Dexibuprofen.Approved
ParoxetineParoxetine may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Dexibuprofen.Approved, Investigational
PhenindioneDexibuprofen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonDexibuprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Dexibuprofen.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexibuprofen.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Dexibuprofen.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Dexibuprofen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Dexibuprofen.Experimental
Polyestradiol phosphateDexibuprofen may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Dexibuprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Dexibuprofen.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Dexibuprofen.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Dexibuprofen.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dexibuprofen.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Dexibuprofen.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Dexibuprofen.Approved, Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Dexibuprofen.Experimental
PromestrieneDexibuprofen may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Dexibuprofen.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Dexibuprofen.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Dexibuprofen.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Dexibuprofen.Investigational
QuinestrolDexibuprofen may increase the thrombogenic activities of Quinestrol.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dexibuprofen.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Dexibuprofen.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Dexibuprofen.Approved, Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Dexibuprofen.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dexibuprofen.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Dexibuprofen.Approved
SecoisolariciresinolDexibuprofen may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Dexibuprofen.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Dexibuprofen.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Dexibuprofen.Investigational
SertralineSertraline may increase the antiplatelet activities of Dexibuprofen.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Dexibuprofen.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dexibuprofen.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Dexibuprofen.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Dexibuprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Dexibuprofen.Experimental
Synthetic Conjugated Estrogens, ADexibuprofen may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BDexibuprofen may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Dexibuprofen.Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Dexibuprofen.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Dexibuprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Dexibuprofen.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Dexibuprofen.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Dexibuprofen.Approved
TiboloneDexibuprofen may increase the thrombogenic activities of Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Dexibuprofen.Investigational
TioclomarolDexibuprofen may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Dexibuprofen.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dexibuprofen.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Dexibuprofen.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Dexibuprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Dexibuprofen.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Dexibuprofen.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Dexibuprofen.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Dexibuprofen.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Dexibuprofen.Approved, Investigational, Withdrawn
VenlafaxineVenlafaxine may increase the antiplatelet activities of Dexibuprofen.Approved
WarfarinDexibuprofen may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexibuprofen.Approved, Investigational
ZeranolDexibuprofen may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Dexibuprofen.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Dexibuprofen.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Dexibuprofen.Withdrawn
Food Interactions
Not Available

References

General References
  1. Hardikar MS: Chiral non-steroidal anti-inflammatory drugs--a review. J Indian Med Assoc. 2008 Sep;106(9):615-8, 622, 624. [PubMed:19552094]
  2. Yoon JS, Jeong DC, Oh JW, Lee KY, Lee HS, Koh YY, Kim JT, Kang JH, Lee JS: The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection. Br J Clin Pharmacol. 2008 Dec;66(6):854-60. doi: 10.1111/j.1365-2125.2008.03271.x. [PubMed:19032727]
  3. Muralidharan S: Pharmacokinetic-pharmacodynamic model of newly developed dexibuprofen sustained release formulations. ISRN Pharm. 2012;2012:451481. doi: 10.5402/2012/451481. Epub 2012 Dec 6. [PubMed:23316393]
  4. Gabard B, Nirnberger G, Schiel H, Mascher H, Kikuta C, Mayer JM: Comparison of the bioavailability of dexibuprofen administered alone or as part of racemic ibuprofen. Eur J Clin Pharmacol. 1995;48(6):505-11. [PubMed:8582471]
  5. Derry S, Best J, Moore RA: Single dose oral dexibuprofen [S(+)-ibuprofen] for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013 Oct 23;(10):CD007550. doi: 10.1002/14651858.CD007550.pub3. [PubMed:24151035]
  6. Gonzalez-Correa JA, Arrebola MM, Martin-Salido E, Munoz-Marin J, de la Cuesta FS, De La Cruz JP: Effects of dexibuprofen on platelet function in humans: comparison with low-dose aspirin. Anesthesiology. 2007 Feb;106(2):218-25. [PubMed:17264714]
  7. 26. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 318-323). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
External Links
KEGG Drug
D03715
PubChem Compound
39912
PubChem Substance
310265120
ChemSpider
36498
BindingDB
50169047
ChEBI
43415
ChEMBL
CHEMBL175
PharmGKB
PA166049174
HET
IBP
Drugs.com
Drugs.com Drug Page
Wikipedia
Dexibuprofen
ATC Codes
M01AE14 — Dexibuprofen
PDB Entries
1eqg / 2bxg / 2pws / 2wd9 / 3ib2 / 3p6h / 4jtr / 4ph9 / 4rs0 / 5jqb
MSDS
Download (44.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Not Yet RecruitingOtherHealthy Volunteers1
1Not Yet RecruitingTreatmentHealthy Volunteers1
3CompletedTreatmentFevers / Respiratory Tract Infections (RTI)1
4CompletedTreatmentOsteoarthritis of the Hip or Knee1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)49-53MSDS
water solubilityInsoluble MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.0684 mg/mLALOGPS
logP3.5ALOGPS
logP3.84ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)4.85ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity60.73 m3·mol-1ChemAxon
Polarizability23.86 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0900000000-cdbb3ff0e6daafa96a33
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0900000000-5f5841ab0d19d92f329f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0900000000-cdbb3ff0e6daafa96a33
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0900000000-eaa0c05cd0af4e11c253
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-0f95bc6329f3e35fe966
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-08fr-0940000000-67dc54562da440ad09d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-aa34b95d477461b9c2cc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-8560b3fd66d81a64b14b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03xr-0900000000-9c4414a9ee3a4c762beb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-066r-1900000000-f2d072114259d50700fb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0aou-3900000000-a474a674fc83022582ad
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-fe15b0b2af67ee4b396a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0910000000-d0e6a673c3c5552f5498
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-5fe1f2909802ac9a796c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03xr-0900000000-cfb78cdc69ad12366199
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-066r-0900000000-7c1ba69d76343263119a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-e04308054c6ff695bd55

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Phenylpropanoic acids
Sub Class
Not Available
Direct Parent
Phenylpropanoic acids
Alternative Parents
Monocyclic monoterpenoids / Aromatic monoterpenoids / Phenylpropanes / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
2-phenylpropanoic-acid / P-cymene / Aromatic monoterpenoid / Monocyclic monoterpenoid / Monoterpenoid / Phenylpropane / Monocyclic benzene moiety / Benzenoid / Monocarboxylic acid or derivatives / Carboxylic acid
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
ibuprofen (CHEBI:43415)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Ashraf Z, Alamgeer, Rasool R, Hassan M, Ahsan H, Afzal S, Afzal K, Cho H, Kim SJ: Synthesis, Bioevaluation and Molecular Dynamic Simulation Studies of Dexibuprofen-Antioxidant Mutual Prodrugs. Int J Mol Sci. 2016 Dec 21;17(12). pii: E2151. doi: 10.3390/ijms17122151. [PubMed:28009827]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Ashraf Z, Alamgeer, Rasool R, Hassan M, Ahsan H, Afzal S, Afzal K, Cho H, Kim SJ: Synthesis, Bioevaluation and Molecular Dynamic Simulation Studies of Dexibuprofen-Antioxidant Mutual Prodrugs. Int J Mol Sci. 2016 Dec 21;17(12). pii: E2151. doi: 10.3390/ijms17122151. [PubMed:28009827]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Ubiquitin protein ligase binding
Specific Function
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appea...
Gene Name
BCL2
Uniprot ID
P10415
Uniprot Name
Apoptosis regulator Bcl-2
Molecular Weight
26265.66 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Modulator
General Function
Transmembrane signaling receptor activity
Specific Function
Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C ...
Gene Name
THBD
Uniprot ID
P07204
Uniprot Name
Thrombomodulin
Molecular Weight
60328.72 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Modulator
General Function
Serine-type endopeptidase activity
Specific Function
Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in t...
Gene Name
PLAT
Uniprot ID
P00750
Uniprot Name
Tissue-type plasminogen activator
Molecular Weight
62916.495 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Transporter activity
Specific Function
FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. Binds satu...
Gene Name
FABP2
Uniprot ID
P12104
Uniprot Name
Fatty acid-binding protein, intestinal
Molecular Weight
15207.165 Da
References
  1. Velkov T, Chuang S, Wielens J, Sakellaris H, Charman WN, Porter CJ, Scanlon MJ: The interaction of lipophilic drugs with intestinal fatty acid-binding protein. J Biol Chem. 2005 May 6;280(18):17769-76. Epub 2005 Feb 18. [PubMed:15722357]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li S: A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi: 10.1523/JNEUROSCI.5045-09.2010. [PubMed:20089905]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Pdz domain binding
Specific Function
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO...
Gene Name
CFTR
Uniprot ID
P13569
Uniprot Name
Cystic fibrosis transmembrane conductance regulator
Molecular Weight
168139.895 Da
References
  1. Devor DC, Schultz BD: Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion. J Clin Invest. 1998 Aug 15;102(4):679-87. [PubMed:9710435]

Drug created on October 21, 2015 09:53 / Updated on August 02, 2018 06:15